Freedom: Scilex shares soar after $100 million investment announcement

Shares of U.S. biopharmaceutical company Scilex Holding (SCLX) jumped sharply in premarket trading after it announced the привлечении strategic investor. Kazakhstan-based investment fund MaxYield Asset Management is ready to purchase shares from a Scilex follow-on offering for up to $100 million at $15 per share—almost twice the July 2 closing price. According to Freedom analyst Natalia Milchakova, the high offering price indicates that the investor is betting on the company’s long-term prospects.

What Scilex is known for

Scilex Holding Company is known as a developer and manufacturer of non-opioid drugs for the treatment of acute and chronic pain. The company is focusing on alternatives to opioid painkillers, which is particularly relevant amid the ongoing opioid crisis in the U.S.

Of interest to investors are Scilex’s developments in weight-loss drugs and early-stage Alzheimer’s disease treatment.

Despite the initial rise, after the deal was announced the company’s shares turned lower and lost about 3.5%. At Freedom, this reaction is explained by the fact that investors still lack information about the terms of Scilex’s cooperation with the new strategic investor and about how the raised funds will be used to grow the business.
According to analysts, the stock’s дальнейшая dynamics will depend on the disclosure of deal details, as well as on the company’s progress in developing new drugs and their commercialization.

Biotech in the stock market

Investor interest in the U.S. biotechnology sector continues to grow thanks to advances in artificial intelligence technologies and continued активности in the M&A market. In early July, AI-model developer Anthropic announced the launch of its own drug-discovery program and unveiled the Claude Science platform for scientific research. Freedom noted that the entry of the largest AI companies into biotechnology can attract additional capital to the industry.

The sector remains attractive not only to technology companies but also to strategic investors. A combination of active M&A deals, the adoption of AI in the development of new drugs, and a packed clinical-trial calendar will continue to support interest in biotech companies. That is why news of attracting a major investor, as in Scilex’s case, is viewed by the market as additional confirmation of the industry’s long-term potential.

Not an individual investment recommendation.